GLA and Fabry disease: In this seminal article, the authors reported that 1-deoxy-galactonojirimycin (DGJ), a potent competitive inhibitor of alpha-galactosidase A (α-Gal A), the deficient protein in Fabry disease (FD), effectively enhanced protein activity in Fabry lymphoblasts when administrated at subinhibitory concentrations.